Malaysiakini10 小时
GSK's respiratory syncytial virus vaccine approved in M'sia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
cilisos.my18 小时
GSK’s Arexvy vaccine for RSV is approved for Malaysian seniors
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
pharmaphorum2 天
‘Real world’ COPD trial gives GSK a dose of reality
Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...
Business Insider1 天
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Sonova Holding AG (CH:SOON – Research Report) and Corbus Pharmaceuticals ...
pharmaphorum3 天
What makes GSK the number one pharmaceutical company in Egypt?
GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...
GSK 在 Phase 2 数据积极后推进 mRNA 流感疫苗研发
德国图宾根和美国波士顿 - GlaxoSmithKline (GSK) 报告了其基于 mRNA 的季节性流感疫苗的令人鼓舞的 Phase 2 结果,该疫苗使用了生物制药公司 CureVac N.V. (NASDAQ:CVAC) 的技术。这项研究达到了所有预定的终点,展示了对甲型和乙型流感毒株的积极免疫反应,以及可接受的安全性和反应原性特征。 这款疫苗候选品基于 CureVac 专有的第二代 mRN ...
BBC18 天
GSK to close antibiotic factory next year
Pharmaceutical firm GlaxoSmithKline (GSK) has confirmed it is shutting one of its UK factories in June 2025. The site in Ulverston, Cumbria, has been producing the antibiotic Zinnat for the Swiss ...
GlaxoSmithKline获TD Cowen维持"持有"评级
TD Cowen维持对GlaxoSmithKline (GSK:LN) (NYSE: GSK)的"持有"评级，目标价保持在1,790.00英镑不变。该公司的立场是在GlaxoSmithKline报告其哮喘药物depemokimab的III期试验结果积极之后做出的，这与关键意见领袖（KOL）预期的约50%哮喘发作减少率一致。这一表现与已获批准的IL-5抑制剂相似。
GSK to speed up development of blood cancer treatment in China
China's health authority has granted GSK's Blenrep blood cancer treatment with a so-called 'Breakthrough Therapy Designation' ...
London South East5 天
Glaxosmithkline Share Chat (GSK)
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...
London South East7 天
Glaxosmithkline Share Chat (GSK)
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...